Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (1304)	9/29/1998 10:02:00 AM
From: Ron	Respond to of 1491

David...it is a pleasure reading your posts once again.

To: David Israel-Rosen who wrote (1304)	9/29/1998 12:14:00 PM
From: Ariella	Read Replies (2) \| Respond to of 1491

NEW PRESS RELEASE TODAY: Pharmos Corp. Dow Jones Newswires -- September 29, 1998 Pharmos To Report Results Of Dexanabinol Study Oct. 7 NEW YORK (Dow Jones)--Pharmos Corp. (PARS) will report results of a two-year study of its dexanabinol treatment for severe head injury at the annual meeting of the Congress of Neurological Surgeons on Oct. 7. In a press release Tuesday, the company said that in the Phase II, double blind, placebo controlled trial, patients received a single injection of dexanabinol within six hours of the initial head injury. So far, 67 patients have been followed over a six-month period. The Phase II trial was conducted at head trauma centers in Israel. The company said it expects to conduct Phase III trials in the U.S. (bold face mine) Pharmos researches, develops and markets proprietary products to treat ophthalmic and neurological disorders.